Form4insider filings, from the source

SEC Form 4 · accession 0001708138-17-000005

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Neil Stahl
Officer — EVP Research and Development
Period of report
Jun 14, 2017
Accepted (ET)
Jun 16, 2017 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJun 14, 2017M20,295$21.25A44,245D
Common StockJun 14, 2017F906$475.56D43,339D
Common StockJun 14, 2017F10,822$475.56D32,517D
Common StockF2Jun 15, 2017S500$462.72D32,017D
Common StockJun 15, 2017S100$463.91D31,917D
Common StockF3Jun 15, 2017S400$464.69D31,517D
Common StockF4Jun 15, 2017S1,244$465.49D30,273D
Common StockF5Jun 15, 2017S185$466.52D30,088D
Common StockF6Jun 15, 2017S300$467.82D29,788D
Common StockF7Jun 15, 2017S900$468.63D28,888D
Common StockF8Jun 15, 2017S2,212$469.53D26,676D
Common StockF9Jun 15, 2017S2,426$470.57D24,250D
Common StockJun 15, 2017S100$471.15D24,150D
Common StockJun 15, 2017S100$472.95D24,050D
Common StockJun 15, 2017S100$474.48D23,950D
Common Stockholding———10,000Iby GRAT
Common Stockholding———5,000Iby GRAT
Common Stockholding———5,647IBy 401(k) Plan

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Non-Qualified Stock Option (right to buy)F10$21.25Jun 14, 2017M20,295D—Dec 18, 2019Common Stock20,2950D

Explanation of responses